BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Core Insights - BioVie Inc. is conducting a hybrid, decentralized Phase 2 clinical trial named SUNRISE-PD to evaluate bezisterim (NE3107) in early-stage Parkinson's disease, focusing on patient access and participation [1][2][3] Group 1: Clinical Trial Design - The SUNRISE-PD trial addresses barriers to participation in clinical trials for Parkinson's disease, such as delayed diagnosis and limited mobility, by allowing home or clinic visits [2][3] - The trial is designed to be flexible, utilizing in-home visits by study nurses and remote assessments via video conferencing, ensuring high-quality data collection through digital tools [4] Group 2: Drug Profile - Bezisterim is an orally available, blood-brain barrier-permeable compound that targets inflammation and insulin resistance, showing promise in improving both motor and non-motor symptoms of Parkinson's disease [5][9] - Previous trials indicated that bezisterim has a favorable safety profile and may modify the progression of Parkinson's disease, particularly in early-stage patients [5][10] Group 3: Enrollment and Partnerships - The trial is enrolling participants aged 41 to 80 diagnosed within the last four years who have not yet started treatment with carbidopa/levodopa or other dopamine receptor agonists [3] - BioVie is collaborating with organizations like The Michael J. Fox Foundation to enhance awareness and facilitate participant enrollment across the U.S. [3] Group 4: Presentation Details - A poster detailing the SUNRISE-PD trial will be presented at the Advanced Therapeutics in Movement & Related Disorders Congress from June 27-30, 2025, highlighting the trial's patient-centric approach [1][6]